Tag: carcinoid cancer
Happy 4th of July from The Carcinoid Cancer Foundation
The Carcinoid Cancer Foundation wishes all carcinoid and neuroendocrine tumor survivors, family, caregivers, friends, colleagues, and the medical community who celebrate Independence Day a happy and safe holiday.
… READ MORE
Carcinoid Cancer Foundation’s May 2011 Symposium Now Online
The Carcinoid Cancer Foundation is pleased to share with you videos from its carcinoid/NET symposium, “Neuroendocrine Tumor Management: The Era of Personalized Medicine,” held on May 1, 2011 at Mt. Sinai Medical Center in New York City.
Following …
READ MOREWorldwide NET Cancer Awareness Day Updates
With less than five months until the second Worldwide NET Cancer Awareness Day on Thursday, November 10, 2011, there have been many exciting developments to share with the carcinoid and NET community.
The first Chinese NET website (www.net.org.tw) …
READ MORENow Recruiting: Carcinoid Syndrome Patients to Participate in Clinical Trial
Ipsen is recruiting patients with a history of carcinoid syndrome to participate in a clinical study to evaluate the effect of Somatuline® Depot (Lanreotide Autogel), a somatostatin analog (SSTa) similar to octreotide, on the control of symptoms …
READ MOREUp-to-the-Minute: News for the Carcinoid and Neuroendocrine Tumor Community
The first device that simultaneously performs PET and MRI scans, a new alpha-emitter-based therapy for NET cancer patients with progressive therapy-resistant tumors, the first–ever randomized virtual clinical trial, over 100 abstracts on carcinoid…
READ MORE1st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy (PRRNT)
Since 1997, when he first used the radiolabeled peptide Y-90 DOTATOC (a somatostatin analogue) to treat a 15-year-old boy with a rare neuroendocrine tumor, called paraganglioma, and saw the boy go from being wheelchair-bound and in terrible pain to …
READ MORECarcinoid Cancer Foundation to Speak on Behalf of NET Cancer Patients at April 12, 2011 FDA Oncologic Drugs Advisory Committee Meeting
Grace Goldstein, Chief Operating Officer of the Carcinoid Cancer Foundation, will speak at the Open Public Hearing segment during the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee Meeting on April 12, 2011 in Silver …
READ MORECarcinoid Patient’s Stepdaughter Runs in Sun Trust National Marathon in Support of Carcinoid Cancer Foundation
If you are in Washington, D.C. on Saturday, March 26th cheer on Alex Todd-Lippock, bib number 3029, when she runs in the 2011 Sun Trust National Marathon in support of the Carcinoid Cancer Foundation (CCF). Ms. Todd-Lippock’s stepmother, Lisa Todd, is…
READ MORECarcinoid Cancer Foundation Symposium Features Leading NET Cancer Specialists & a Patient Panel
What are the most state-of-the-art treatments for carcinoid and NET cancer patients today? Join us on May 1st when the Carcinoid Cancer Foundation presents its 14th Annual Symposium, “Neuroendocrine Tumor Management: The Era of Personalized…
READ MORENeuroendocrine Tumors Featured on Healthy Body, Healthy Mind Television Series
For a comprehensive overview of neuroendocrine tumors, watch this fascinating video on the Healthy Body, Healthy Mind television series. Every episode on the health and wellness TV series focuses on the stories of real people; people who are working…
READ MORE